Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy

Epilepsy Research

Volumn 89, Issue 2-3, 2010, Pages 278-285

  Ben Menachem, E ^a   Gabbai, A A ^b   Hufnagel, A ^c   Maia, J ^d   Almeida, L ^e   Soares da Silva, P ^d,f  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^e UNIVERSITY OF AVEIRO   (Portugal)

^f University of Porto   (Portugal)

Author keywords

Antiepileptic drugs; Clinical trials randomized controlled; Eslicarbazepine acetate; Partial onset seizures

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ESLICARBAZEPINE ACETATE; ETIRACETAM; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION DISORDER; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; GOOD CLINICAL PRACTICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VOMITING;

ADULT; ANTICONVULSANTS; DIBENZAZEPINES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; EPILEPSIES, PARTIAL; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; NAUSEA; SEIZURES; TREATMENT OUTCOME;

EID: 77951297857     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.01.014     Document Type: Article

References (18)

1. Almeida L., Bialer M., Soares-da-Silva P. Eslicarbazepine acetate. The Treatment of Epilepsy 2009, 485-498. Blackwell Publishing, Oxford. S. Shorvon, E. Perucca, J. Engel (Eds.).
2. Almeida L., Falcão A., Maia J., Mazur D., Gellert M., Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J. Clin. Pharmacol. 2005, 45:1062-1066.
3. Almeida L., Potgieter J.H., Maia J., Potgieter M.A., Mota F., Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur. J. Clin. Pharmacol. 2008, 64:267-273.
4. Ambrosio A.F., Soares-Da-Silva P., Carvalho C.M., Carvalho A.P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 2002, 27:121-130.
5. Benes J., Parada A., Figueiredo A.A., Alves P.C., Freitas A.P., Learmonth D.A., Cunha R.A., Garrett J., Soares-da-Silva P. Anticonvulsant and sodium channel-blocking properties of novel 10,11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J. Med. Chem. 1999, 42:2582-2587.
6. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009, 83:1-43.
7. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981, 22:489-501.
8. Elger C., Bialer M., Cramer J.A., Maia J., Almeida L., Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007, 48:497-504.
9. Elger C., Halász P., Maia J., Almeida L., Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009, 50:454-463.
10. EMEA/CPMP, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders. London, 16 November 2000 (CPMP/EWP/566/98 rev 1).
11. Falcao A., Maia J., Almeida L., Mazur D., Gellert M., Soares-da-Silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm. Drug Dispos. 2007, 28:249-256.
12. Fontes-Ribeiro C., Macedo T., Nunes T., Neta C., Vasconcelos T., Cerdeira R., Lima R., Rocha J.F., Falcao A., Almeida L., Soares-da-Silva P. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R&D 2008, 9:447-454.
13. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., Theodore W.H., Bazil C., Stern J., Schachter S.C., Bergen D., Hirtz D., Montouris G.D., Nespeca M., Gidal B., Marks W.J., Turk W.R., Fischer J.H., Bourgeois B., Wilner A., Faught R.E., Sachdeo R.C., Beydoun A., Glauser T.A. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62:1261-1273.
14. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342:314-319.
15. Maia J., Vaz-da-Silva M., Almeida L., Falcão A., Silveira P., Guimarães S., Graziela P., Soares-da-Silva P. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R&D 2005, 6:201-206.
16. Perucca E., Falcão A., Maia J., Almeida L., Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with epilepsy. Epilepsia 2009, 50(Suppl. 4):196.
17. Perucca E., French J., Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007, 6:793-804.
18. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129:18-35.